Primers for RT-qPCR. by Luqiong Liu (11537092)

“…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Subjects:

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments by Animesh Gopal (18521180)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). by Ayana Ablayeva (22103708)

Subjects: